Mechanisms of initiation and progression of intestinal fibrosis in IBD

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 1, 2014, Pages 53-65

  Latella, Giovanni ^a   Di Gregorio, Jacopo ^a   Flati, Vincenzo ^a   Rieder, Florian ^b   Lawrance, Ian C ^c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Crohn's disease; Extracellular matrix; Inflammatory bowel disease; Intestinal fibrosis; Matrix metalloproteinases; Tissue inhibitors of metalloproteinases; Ulcerative colitis

Indexed keywords

GASTROINTESTINAL AGENT;

APOPTOSIS; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE COURSE; EXTRACELLULAR MATRIX; FIBROSIS; HUMAN; INTESTINE MUCOSA; METABOLISM; PATHOLOGY;

APOPTOSIS; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FIBROSIS; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA;

EID: 84919451848     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.968863     Document Type: Review

References (99)

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94.
2. Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol 2012;18: 3790-9.
3. Fiocchi C, Lund PK. Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2011; 300:G677-83.
4. Rieder F, Fiocchi C. Mechanisms of tissue remodeling in inflammatory bowel disease. Dig Dis 2013;31:186-93.
5. Rieder F, Fiocchi C. Intestinal fibrosis in IBD-a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 2009; 6:228-35.
6. Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR. Fibrogenesis in Crohn's disease. Am J Gastroenterol 2007;102:439-48.
7. Rieder F, Zimmermann EM, Feza H Remzi FH, Sandborn WJ. Crohn's disease complicated by strictures: a systematic review. Gut 2013;62:1072-84.
8. Lawrance IC, Maxwell L, Doe WF. Inflammation location, but not type, determines the increase in TGFb-1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis 2001;7:16-26.
9. Gordon LO, Agrawal N, Goldblum JR, Fiocchi C, Rieder F. Fibrosis in ulcerative colitis-mechanisms, features and consequences of a neglected problem. Inflamm Bowel Dis 2014; In Press.
10. Gazouli M, Pachoula I, Panayotou I, Mantzaris G, Chrousos G, Anagnou NP, et al. NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease. World J Gastroenterol 2010;16:1753-8.
11. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18: 1028-40.
12. Speca S, Giusti I, Rieder F, Latella G. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol 2012;18:3635-61.
13. Rieder F, Karrasch T, Ben-Horin S, Schirbel A, Ehehalt R, Wehkamp J, et al. Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing. J Crohns Colitis 2012;6:373-85.
14. Cosnes J, Nion-larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppres-sants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-41.
15. Angelucci E, Cesarini M, Gentile P, Necozione S, Fieri G, Caprilli R, et al. Available medical therapies do not affect development of major complications and need for surgery in Crohn's isease: Long-term prospective study on a population of 193 consecutive patients. J Crohns Colitis 2011;5: S120-1.
16. Latella G, Sferra R, Speca S, Vetuschi S, Gaudio E. Can we prevent, reduce or reverse intestinal fibrosis in IBD? Eur Rev Med Pharmacol Sci 2013;17:1283-304.
17. Rieder F, de Bruyn JR, Pham BT, Katsanos K, Annese V, Higgins PD, et al. Results of the 4th Scientific Workshop of the ECCO (Group II): Markers of intestinal fibrosis in inflammatory bowel disease. J Crohns Colitis 2014;doi: 10.1016/j.crohns.2014.03.009; Epub ahead of print.
18. Li J, Qiu SJ, She WM, Wang FP, Gao H, Li L, et al. Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis. PLoS One 2012;7:e39307.
19. Latella G, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, et al. Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis 2014;doi: 10.1016/j.crohns.2014.03.008; Epub ahead of print.
20. Lakatos G, Hritz I, Varga MZ, Juhász M, Miheller P, Cierny G, et al. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. Dig Dis 2012;30:289-95.
21. Luna J, Masamunt MC, Lawrance IC, Sans M. Mesenchy-mal cell proliferation and programmed cell death: key players in fibrogenesis and new targets for therapeutic intervention. Am J Physiol Gastrointest Liver Physiol 2011;300:G703-8.
22. Rieder F, Lawrance IC, Leite A, Sans M. Predictors of fibrostenotic Crohn's disease. Inflamm Bowel Dis 2011; 17:2000-7.
23. Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, Leakey NA, et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 2009;58:777-89.
24. Fichtner-Feigl S, Young CA, Kitani A, Geissler EK, Schlitt HJ, Strober W. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 2008; 135:2003-13.
25. Rieder F, Kessler S, Sans M, Fiocchi C. Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol 2012;303:G786-801.
26. Vallance BA, Gunawan MI, Hewlett B, Bercik P, Van Kampen C, Galeazzi F, et al. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol 2005;289:G116-28.
27. Latella G, Vetuschi A, Sferra R, Zanninelli G, D'Angelo A, Catitti V, et al. Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis. Eur J Clin Invest 2009;39:145-56.
28. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770-4.
29. Nomura M, Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 1998; 393:786-90.
30. Yang X, Li C, Hu X, Deng C. The tumor suppressor Smad4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc Natl Acad Sci USA 1998;95: 3667-72.
31. Panganiban RA, Day RM. Hepatocyte growth factor in lung repair and pulmonary fibrosis. Acta Pharmacol Sin 2011;32: 12-20.
32. Weiskirchen R, Meurer SK, Gressner OA, Herrmann J, Borkham-Kamphorst E, Gressner AM. BMP-7 as antagonist of organ fibrosis. Front Biosci(Landmark Ed) 2009;14:4992-5012.
33. Baghy K, Iozzo RV, Kovalszky I. Decorin-TGFb axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem 2012;60:262-8.
34. Latella G, Vetuschi A, Sferra R, Speca S, Gaudio E. Local-izationof avb6 integrin-TGF-b1/Smad3, mTOR and PPARg in experimental colorectal fibrosis. Eur J Histochemistry 2013;57:271-7.
35. Katsumoto TR, Violette SM, Sheppard D. Blocking TGFb via inhibition of the avb6 integrin: a possible therapy for systemic sclerosis interstitial lung disease. Int J Rheumatol 2011;2011:208219.
36. Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007;12:112-24.
37. Wang S, Wilkes MC, Leof EB, Hirschberg R. Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 2010;298:F142-9.
38. Massey DC, Bredin F, Parkes M. Case report Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 2008;57:1294-6.
39. Dumortier J, Lapalus MG, Guillaud O, Poncet G, Gagnieu MC, Partensky C, et al. Everolimus for refractory Crohn's disease: a case report. Inflamm Bowel Dis 2008;14: 874-7.
40. Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008; 103:2284-92.
41. Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, et al. Activation of canonical Wnt signalling is required for TGF-b-mediated fibrosis. Nat Commun 2012;3:735.
42. Wu B, Crampton SP, Hughes CC. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 2007;26:227-39.
43. Henderson WR Jr, Chi EY, Ye X, Nguyen C, Tien YT, Zhou B, et al. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci USA 2010;107:14309-14.
44. Horn A, Palumbo K, Cordazzo C, Dees C, Akhmetshina A, Tomcik M, et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum 2012;64:2724-33.
45. Fabian SL, Penchev RR, St-Jacques B, Rao AN, Sipilä P, West KA, et al. Hedgehog-Gli pathway activation during kidney fibrosis. Am J Pathol 2012;180:1441-53.
46. Horn A, Kireva T, Palumbo-Zerr K, Dees C, Tomcik M, Cordazzo C, et al. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis 2012;71:785-9.
47. Liu T, Hu B, Choi YY, Chung M, Ullenbruch M, Yu H, et al. Notch1 signaling in FIZZ1 induction of myofi-broblast differentiation. Am J Pathol 2009;174:1745-55.
48. Bielesz B, Sirin Y, Si H, Niranjan T, Gruenwald A, Ahn S, et al. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest 2010;120:4040-54.
49. Chen Y, Zheng S, Qi D, Zheng S, Guo J, Zhang S, et al. Inhibition of notch signaling by a c-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS One 2012;7:e46512.
50. Jin Y, Ratnam K, Chuang PY, Fan Y, Zhong Y, Dai Y, et al. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat Med 2012;18:580-8.
51. Ghia JE, Li N, Wang H, Collins M, Deng Y, El-Sharkawy RT, et al. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 2009;137:1649-60.
52. Mann DA, Oakley F. Serotonin paracrine signaling in tissue fibrosis. Biochimica et Biophysica Acta 2013;1832:905-10.
53. Fabre A, Marchal-Sommé J, Marchand-Adam S, Quesnel C, Borie R, Dehoux M, et al. Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur Respir J 2008;426-36.
54. Hamasaki Y, Doi K, Maeda-Mamiya R, Ogasawara E, Katagiri D, Tanaka T, et al. A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1. Am J Physiol Renal Physiol 2013;305:F1796-803.
55. Zhang GY, Cheng T, Zheng MH, Yi CG, Pan H, Li ZJ, et al. Activation of peroxisome proliferator-activated receptorgamma inhibits transforming growth factor-beta1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro. Arch Dermatol Res 2009;301:515-22.
56. Zhang F, Lu Y, Zheng S. Peroxisome proliferator-activated receptor-g cross-regulation of signaling events implicated in liver fibrogenesis. Cell Signal 2012;24:596-605.
57. Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, et al. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009;60:2822-9.
58. Pirat C, Farce A, Lebègue N, Renault N, Furman C, Millet R, et al. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. J Med Chem 2012;55:4027-61.
59. Speca S, Rousseaux C, Dubuquoy C, Vetuschi A, Sferra R, Bertin B, et al. GED-0507-34 Levo, a novel modulator of PPARgamma as new therapeutic strategy in the treatment of intestinal fibrosis. J Crohn Colitis 2013;7:S31-2.
60. Karmiris K, Koutroubakis IE, Kouroumalis EA. Leptin, adiponectin, resistin, and ghrelin-implications for inflammatory bowel disease. Mol Nutr Food Res 2008;52:855-66.
61. Fink C, Karagiannides I, Bakirtzi K, Pothoulakis C. Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis 2012;18:1550-7.
62. Yamauchi T, Iwabu M, Okada-Iwabu M, Kadowaki T. Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab 2014;28:15-23.
63. Marra F, Navari N, Vivoli E, Galastri S, Provenzano A. Modulation of liver fibrosis by adipokines. Dig Dis 2011; 29:371-6.
64. Mizuno S, Matsumoto K, Nakamura T. HGF as a reno-trophic and anti-fibrotic regulator in chronic renal disease. Front Biosci 2008;13:7072-86.
65. Chakraborty S, Chopra P, Hak A, Dastidar SG, Ray A. Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis. Expert Opin Investig Drugs 2013;22:499-515.
66. Weiskirchen R, Meurer SK. BMP-7 counteracting TGF-beta1 activities in organ fibrosis. Front Biosci (Landmark Ed) 2013;18:1407-34.
67. Bi WR, Xu GT, Lv LX, Yang CQ. The ratio of transforming growth factor-b1/bone morphogenetic protein-7 in the progression of the epithelial-mesenchymal transition contributes to rat liver fibrosis. Genet Mol Res 2014;13:1005-14.
68. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003;9:964-8.
69. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 2012;18: 396-404.
70. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010;19:491-505.
71. Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG, et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-b-SMAD pathway. Dev Cell 2010;19:831-44.
72. Imajo M, Miyatake K, Iimura A, Miyamoto A, Nishida E. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/b-catenin signalling. EMBO J 2012;31: 1109-22.
73. Lin YT, Ding JY, Li MY, Yeh TS, Wang TW, Yu JY. YAP regulates neuronal differentiation through Sonic hedgehog signaling pathway. Exp Cell Res 2012;318:1877-88.
74. Kuro-o M. Klotho in health and disease. Curr Opin Nephrol Hypertens 2012;21:362-8.
75. Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011;286:8655-65.
76. Zhou L, Li Y, Zhou D, Tan RJ, Liu Y. Loss of Klotho contributes to kidney injury by derepression of Wnt/b-catenin signaling. J Am Soc Nephrol 2013;24:771-85.
77. Simic P, Williams EO, Bell EL, Gong JJ, Bonkowski M, Guarente L. SIRT1 suppresses the epithelial-to-mesenchy-mal transition in cancer metastasis and organ fibrosis. Cell Rep 2013;3:1175-86.
78. Wang Y, Shi X, Qi J, Li X, Uray K, Guan X. SIRT1 inhibits the mouse intestinal motility and epithelial proliferation. Am J Physiol Gastrointest Liver Physiol 2012;302:G207-17.
79. Jiang X, Tsitsiou E, Herrick SE, Lindsay MA. MicroRNAs and the regulation of fibrosis. FEBS J 2010;277:2015-21.
80. Pekow JR, Kwon JH. MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:187-93.
81. Chen Y, Ge W, Xu L, Qu C, Zhu M, Zhang W, et al. miR-200b is involved in intestinal fibrosis of Crohn's disease. Int J Mol Med 2012;29:601-6.
82. Ravi A, Garg P, Sitaraman SV. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis 2007;13:97-107.
83. Pender SL. Do metalloproteinases contribute to tissue destruction or remodeling in the inflamed gut? Inflamm Bowel Dis 2008;14:S136-7.
84. Greenlee KJ, Werb Z, Reenle E, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev 2007;87:69-98.
85. Lawrance IC, Wu F, Leite AZA, Willis J, West GA, et al. A murine model of chronic-inflammation-induced intestinal fibrosis down-regulated by antisense NF-kB Gastroenterol-ogy. 2003;125:1750-61.
86. Strup-Perrot C, Mathé D, Linard C, Violot D, Milliat F, François A, et al. Global gene expression profiles reveal an increase in mRNA levels of collagens, MMPs, and TIMPs in late radiation enteritis. Am J Physiol Gastrointest Liver Physiol 2004;287:G875-85.
87. Singh KP, Gerard HC, Hudson AP, Boros DL. Differential expression of collagen, MMP, TIMP and fibrogenic-cytokine genes in the granulomatous colon of Schistosoma manso-niinfected mice. Ann Trop Med Parasitol 2006;100:611-20.
88. Clutterbuck AL, Asplin KE, Harris P, Allaway D, Mobasheri A. Targeting matrix metalloproteinases in inflammatory conditions. Curr Drug Targets 2009;10:1245-54.
89. Spinelli A, Correale C, Szabo H, Montorsi M. Intestinal fibrosis in Crohn's disease: medical treatment or surgery? Curr Drug Targets 2010;11:242-8.
90. Latella G, Caprilli R, Travis S. In favour of early surgery in Crohn's disease: a hypothesis to be tested. J Crohn Colitis 2011;5:1-4.
91. Caprilli R, Latella G, Frieri G. Treatment of inflammatory bowel diseases: to heal the wound or to heal the sick? J Crohns Colitis 2012;6:621-5.
92. Dignass A, van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, et al. European Crohn's and Colitis Organisation (ECCO). The second European eviden-cebased consensus on the diagnosis and management of Crohn's disease: Current management. J Crohn Colitis 2010; 4:28-62.
93. Samimi R, Flasar MH, Kavic S, Tracy K, Cross RK. Outcome of medical treatment of stricturing and penetrating Crohn's disease: a retrospective study. Inflamm Bowel Dis 2010;16:1187-94.
94. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Shreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
95. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-9.
96. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500.
97. Bouguen G, Peyrin-biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut 2011;60:1178-81.
98. Bettenworth D, Rieder F. Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs-a systematic review. Fibrogenesis Tissue Repair 2014;7:5.
99. Koboziev I, Karlsson F, Zhang S, Grisham MB. Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies. Inflamm Bowel Dis 2011;17: 1229-45.